Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31689751 | 1.00 | TAAR1 (0.59) | TAAR1MTNR1AMTNR1BAOC3LMNA | |
| SCHEMBL30800373 | 0.85 | MTNR1A (0.60) | TAAR1MTNR1AMTNR1BAOC3CASP3 | |
| SCHEMBL7331644 | 0.85 | MTNR1A (0.60) | TAAR1MTNR1AMTNR1BAOC3CASP3 | |
| SCHEMBL4684928 | 0.85 | CA12 (0.55) | MTNR1ALMNASMN1; SMN2CA12CA1 | |
| SCHEMBL3065637 | 0.85 | MTNR1A (0.52) | TAAR1MTNR1AMTNR1BLMNASMN1; SMN2 | |
| SCHEMBL4685285 | 0.84 | L3MBTL1 (0.54) | MTNR1ALMNA | |
| SCHEMBL29590071 | 0.84 | LMNA (0.59) | TAAR1MTNR1AMTNR1BLMNASMN1; SMN2 | |
| SCHEMBL266525 | 0.84 | MTNR1A (0.63) | TAAR1MTNR1AMTNR1BLMNACASP3 | |
| SCHEMBL30365164 | 0.84 | MTNR1A (0.63) | TAAR1MTNR1AMTNR1BLMNACASP3 | |
| SCHEMBL362209 | 0.84 | LMNA (0.59) | TAAR1MTNR1AMTNR1BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | claimed |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-12-18 | — | — | US | claimed |
| US-7427613-B2 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-23 | — | — | US | claimed |
| EP-1708992-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | claimed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | claimed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | claimed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | claimed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | claimed |
| CN-105121430-B | Conditioning agent for treating the LADA orphan receptor γ related to the biostearin of inflammatory disease (ROR γ) | 葛兰素集团有限公司 | 2017-06-16 | — | — | CN | disclosed |
| CN-105263915-A | Glutamase inhibitors and method of use | AGIOS PHARMACEUTICALS INC | 2016-01-20 | — | — | CN | disclosed |
| EP-2755949-B1 | FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | BAYER IP GMBH (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-9090600-B2 | Fungicidal 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadizol-5(4H)-one derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140349848-A1 | FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| EP-1433786-A1 | Benzoxazole compound and pharmaceutical composition containing the compound | Kowa Company Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| CN-1494542-A | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ������˹ҩƷ��˾ | 2004-05-05 | — | — | CN | disclosed |
| US-6653334-B1 | Electively activate peroxisome proliferator activated receptors | KOWA CO., LTD. (JP) | 2003-11-25 | — | — | US | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| EP-0706521-A1 | NOVEL IMIDES | CELGENE CORPORATION (US) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | TAAR1 45/4885MTNR1A 176/4885MTNR1B 189/4885 |
| US-20140349848-A1 | FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | CYP4X1, CYP4B1, CYP4Z1 | TAAR1 1325/4885MTNR1A 1033/4885MTNR1B 1107/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | TAAR1 1785/4885MTNR1A 2115/4885MTNR1B 838/4885 |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | REN, AGTR1, ACE | TAAR1 1785/4885MTNR1A 2115/4885MTNR1B 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.